Welcome to our dedicated page for Clearmind Medici SEC filings (Ticker: CMND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Clearmind Medicine Inc. (CMND) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. Clearmind submits current reports on Form 6-K and annual reports on Form 20-F under the Securities Exchange Act of 1934, reflecting its status as a clinical-stage psychedelic pharmaceutical biotech company listed on Nasdaq and the Frankfurt Stock Exchange.
Through these filings, investors can review press releases that are formally incorporated by reference into Clearmind’s registration statements on Form F-3 and Form S-8. Recent Form 6-K reports have attached announcements about the FDA-approved Phase I/IIa clinical trial of CMND-100 for alcohol use disorder, including positive top-line results from the first cohort, Data and Safety Monitoring Board approval to continue the trial, and expansion of the multinational clinical-site network. Other 6-K filings describe capital-raising transactions such as registered direct offerings of common shares and pre-funded warrants, with stated uses of proceeds for operating expenses, research and development, clinical and pre-clinical testing, working capital, and general corporate purposes.
Clearmind’s filings also document corporate actions relevant to CMND stock, including a 1-for-40 reverse share split and Nasdaq notifications regarding minimum bid price and stockholders’ equity requirements. These documents outline how the company has addressed exchange listing criteria and how related matters are monitored by Nasdaq. In addition, the filings identify Clearmind’s principal executive offices in Vancouver, British Columbia, and provide details on its intellectual property-focused business model and clinical-stage status.
On Stock Titan, Clearmind’s SEC filings are updated as new documents are posted to EDGAR. AI-powered summaries help explain the context and key points of lengthy reports, making it easier to locate information on clinical trial disclosures, financing terms, and listing compliance without reading every page in detail. Users can also review historical filings to understand how Clearmind’s development programs, capital structure, and regulatory communications have evolved over time.
Clearmind Medicine Inc. is offering 3,991,768 common shares and pre-funded warrants for up to 1,518,000 additional shares at $0.25 per share and $0.2499 per warrant, for gross proceeds of approximately $1.38 million before expenses. The company estimates net proceeds of about $1.3 million. Common shares outstanding were 16,671,256 as of November 14, 2025 and are expected to reach 22,181,024 if all pre-funded warrants are exercised. The cash will support general corporate purposes, including operating expenses, R&D and clinical trials.
Clearmind is a clinical-stage psychedelic medicine company developing MEAI-based treatments for alcohol use disorder, obesity, metabolic disorders and other addictive behaviors, with an ongoing multinational Phase I/IIa trial of CMND‑100 at sites including Yale and Johns Hopkins. The company recently received a Nasdaq notice for not meeting the $2.5 million minimum stockholders’ equity requirement, and its latest audited financials include substantial doubt about its ability to continue as a going concern. Management expects this offering, prior financings, warrant exercises and note conversions to help improve equity and support continued development.
Clearmind Medicine Inc. furnished a Form 6-K that attaches a press release titled “Clearmind Medicine Receives Final Approval to Expand its FDA Regulated Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center.”
The first paragraph of the press release is incorporated by reference into the company’s registration statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293) and Form S-8 (File No. 333-283695).
Clearmind Medicine entered a definitive securities purchase agreement for a registered direct offering of 958,222 common shares and pre-funded warrants to purchase up to 2,984,146 common shares, priced at $0.20 per share and $0.1999 per pre-funded warrant.
The pre-funded warrants are immediately exercisable at an exercise price of $0.0001 per share and may be exercised on a cashless basis, subject to a 4.99% beneficial ownership cap. Closing is expected on or about November 14, 2025, subject to customary conditions. The transaction is expected to generate approximately $0.788 million in aggregate gross proceeds. The company plans to use net proceeds, together with existing cash, for general corporate purposes, including operating expenses, R&D, working capital, potential acquisitions, and capital expenditures.
Clearmind Medicine Inc. (CMND) launched a primary offering of 958,222 common shares at $0.20 per share and pre-funded warrants to purchase up to 2,984,143 common shares at $0.1999, together with the common shares issuable upon exercise of those warrants. Each pre-funded warrant is immediately exercisable for one share at $0.0001 and remains outstanding until fully exercised, subject to 4.99% (or 9.99% at holder election) beneficial ownership limits.
The company expects gross proceeds of $788,175 before expenses and estimates net proceeds of approximately $0.78 million, to be used for general corporate purposes, including R&D and working capital. Shares outstanding were 9,601,441 as of November 12, 2025; the company states 13,543,806 would be outstanding assuming full exercise of pre-funded warrants.
CMND disclosed a Nasdaq notice of non-compliance with the $2.5 million stockholders’ equity requirement after reporting $1,065,668 of equity and has until December 18, 2025 to submit a compliance plan. Delivery of securities is expected on or about November 14, 2025, subject to customary closing conditions.
Clearmind Medicine (CMND) filed a Form 6-K reporting it received a Nasdaq notification regarding a minimum stockholders’ equity deficiency. The filing attaches a press release titled “Clearmind Medicine Receives Nasdaq Notification Regarding Minimum Stockholders’ Equity Deficiency.”
The first four paragraphs of the press release are incorporated by reference into the company’s shelf registration statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293) and its Form S-8 (File No. 333-283695).
Clearmind Medicine (CMND) furnished a Form 6-K announcing a press release titled “Clearmind Expands Global IP Protection for MEAI in Depression Treatment with New South Korea Patent Filing.”
The filing also states that the first four paragraphs of the press release are incorporated by reference into the company’s Registration Statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293) and Form S-8 (File No. 333-283695) as of November 5, 2025.
Clearmind Medicine Inc. (CMND) furnished a Form 6-K reporting balance-sheet activity and an IP update. The company disclosed that on October 30–31, 2025, an aggregate of $1,045,062 of outstanding amounts due under previously issued convertible promissory notes was converted into 885,000 common shares. This reduces note balances while increasing the equity base.
The filing also attaches a press release announcing the publication of a U.S. patent application for its non-hallucinogenic neuroplastogen MEAI therapy aimed at cocaine addiction. Additionally, the Form 6-K and the first three paragraphs of the press release are incorporated by reference into the company’s effective shelf and equity compensation registration statements (Form F-3 File Nos. 333-275991, 333-270859, 333-273293; Form S-8 File No. 333-283695).
Clearmind Medicine (CMND) furnished a Form 6-K that attaches a press release titled “Clearmind Medicine Completes First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder.” The filing also states that the first four paragraphs of this press release are incorporated by reference into the company’s effective registration statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293) and Form S-8 (File No. 333-283695), becoming part of those filings to the extent not later superseded.
Clearmind Medicine (CMND) filed a Form 6-K announcing the appointment of Mary-Elizabeth Gifford as Chief of Global Impact to advance US partnerships and governmental engagement. The filing attaches a press release dated October 27, 2025.
The first, second, fifth and sixth paragraphs of that release are incorporated by reference into Clearmind’s Registration Statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293) and Form S-8 (File No. 333-283695).
Clearmind Medicine Inc. (CMND) furnished a Form 6-K for October 2025, attaching a press release titled “Clearmind Medicine Enrolls Last Patient for the First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder.” The press release is included as Exhibit 99.1.
The filing states that the first three paragraphs of the press release are incorporated by reference into Clearmind’s Registration Statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293) and Form S-8 (File No. 333-283695) from the date this report is submitted, to the extent not superseded by later filings.